Sensus Healthcare Management
Management criteria checks 4/4
Sensus Healthcare's CEO is Joe Sardano, appointed in Jun 2010, has a tenure of 14.5 years. total yearly compensation is $687.60K, comprised of 65.4% salary and 34.6% bonuses, including company stock and options. directly owns 7.17% of the company’s shares, worth $9.37M. The average tenure of the management team and the board of directors is 3.4 years and 7.9 years respectively.
Key information
Joe Sardano
Chief executive officer
US$687.6k
Total compensation
| CEO salary percentage | 65.4% |
| CEO tenure | 14.5yrs |
| CEO ownership | 7.2% |
| Management average tenure | 3.4yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 19
Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
Nov 12At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
Oct 03Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
May 12Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
Apr 16Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 11There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital
Oct 17Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger
Jul 04Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop
Mar 14Do Sensus Healthcare's (NASDAQ:SRTS) Earnings Warrant Your Attention?
Mar 06Sensus Healthcare (NASDAQ:SRTS) Could Become A Multi-Bagger
Oct 11Sensus Healthcare Q2 GAAP EPS, revenue beats
Aug 04Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month
May 21Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts
May 11Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist
Apr 29Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality
Apr 01Are Investors Undervaluing Sensus Healthcare, Inc. (NASDAQ:SRTS) By 31%?
Dec 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$9m |
| Jun 30 2024 | n/a | n/a | US$7m |
| Mar 31 2024 | n/a | n/a | US$5m |
| Dec 31 2023 | US$688k | US$450k | US$485k |
| Sep 30 2023 | n/a | n/a | -US$896k |
| Jun 30 2023 | n/a | n/a | US$2m |
| Mar 31 2023 | n/a | n/a | US$6m |
| Dec 31 2022 | US$754k | US$400k | US$24m |
| Sep 30 2022 | n/a | n/a | US$27m |
| Jun 30 2022 | n/a | n/a | US$25m |
| Mar 31 2022 | n/a | n/a | US$21m |
| Dec 31 2021 | US$628k | US$375k | US$4m |
| Sep 30 2021 | n/a | n/a | -US$181k |
| Jun 30 2021 | n/a | n/a | -US$2m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$510k | US$375k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$467k | US$375k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$3m |
| Jun 30 2019 | n/a | n/a | -US$2m |
| Mar 31 2019 | n/a | n/a | -US$3m |
| Dec 31 2018 | US$538k | US$360k | -US$2m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$3m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | US$490k | US$324k | -US$4m |
Compensation vs Market: Joe's total compensation ($USD687.60K) is about average for companies of similar size in the US market ($USD646.00K).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe Sardano (71 yo)
14.5yrs
Tenure
US$687,599
Compensation
Mr. Joseph C. Sardano, also known as Joe, serves as Director at BioFlorida Inc since August 2021. He Co-Founded Sensus Healthcare, Inc. in 2010 and has been its Chairman of the Board, Chief Executive Offic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.5yrs | US$687.60k | 7.17% $ 9.4m | |
| President | 7.9yrs | US$452.53k | 0.46% $ 596.5k | |
| Chief Financial Officer | 4.9yrs | US$357.06k | 0.25% $ 320.7k | |
| Chief Operating Officer | 1.9yrs | no data | 0.060% $ 77.8k | |
| Chief Technology Officer | 1.9yrs | no data | 0.061% $ 79.7k | |
| Vice President of Marketing | 1.9yrs | no data | no data |
3.4yrs
Average Tenure
46yo
Average Age
Experienced Management: SRTS's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.5yrs | US$687.60k | 7.17% $ 9.4m | |
| President | less than a year | US$452.53k | 0.46% $ 596.5k | |
| Independent Director | 8.4yrs | US$75.00k | 0.28% $ 370.3k | |
| Member of Medical Advisory Board | 7.9yrs | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 7.9yrs | no data | no data | |
| Member of Medical Advisory Board | 7.8yrs | no data | no data | |
| Independent Director | 9.2yrs | US$75.00k | 0.061% $ 79.7k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 7.1yrs | no data | no data | |
| Member of the Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
7.9yrs
Average Tenure
71yo
Average Age
Experienced Board: SRTS's board of directors are considered experienced (7.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 07:12 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sensus Healthcare, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |
| Ilya Zubkov | Freedom Broker |